Show simple item record

Estudio fase III aleatorizado de terapia sistémica estándar (SST) versus terapia sistémica estándar más tratamiento definitivo (cirugía o radiación) del tumor primario en cáncer metastásico de próstata

dc.contributor.advisorVarela Ramirez, Rodolfo
dc.contributor.authorBecerra Mendez, Luis Miguel
dc.contributor.authorAparicio, Ana
dc.contributor.authorChapin, Brian F.
dc.contributor.authorValicenti, Richard
dc.contributor.authorVarela Ramirez, Rodolfo
dc.contributor.authorCabrera Fierro, Marino
dc.contributor.otherCabrera Fierro, Marino
dc.coverage.spatialBogotaspa
dc.coverage.temporal20 septiembre 2019spa
dc.date.accessioned2021-02-22T16:12:24Z
dc.date.available2021-02-22T16:12:24Z
dc.date.issued2021-01-25
dc.identifier.urihttp://hdl.handle.net/10654/37413
dc.description.abstractEl tratamiento definitivo del tumor primario se ha reservado tradicionalmente para el tratamiento de cáncer localizado de próstata (PC) pero un número cada vez mayor de estudios sugieren que mejora la sobrevida global (OS) y la sobrevida específica del cáncer (CSS) de hombres con enfermedad metastásica (≥ M1a). El tratamiento definitivo del tumor primario puede provocar un efecto en la biología de la enfermedad que contribuye al mejoramiento en los resultados. Se quiere comparar la sobrevida global en pacientes con cáncer metastásico de próstata que son aleatorizados a terapia sistémica estándar (SST) más tratamiento definitivo del tumor primario versus solo terapia sistémica estándar.spa
dc.format.mimetypeapplicaction/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEstudio fase III aleatorizado de terapia sistémica estándar (SST) versus terapia sistémica estándar más tratamiento definitivo (cirugía o radiación) del tumor primario en cáncer metastásico de próstataspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2*
dc.type.localTesis/Trabajo de grado - Monografía - Especializaciónspa
dc.description.abstractenglishDefinitive treatment of the primary tumor has traditionally been reserved for the treatment of localized prostate cancer (PC), but an increasing number of studies suggest that it improves the overall survival (OS) and cancer-specific survival (CSS) of men with metastatic disease (≥ M1a). Definitive treatment of the primary tumor may cause an effect on the biology of the disease that contributes to improved outcomes. We want to compare the overall survival in patients with metastatic prostate cancer who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus only standard systemic therapy.spa
dc.title.translatedRandomized phase III study of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancerspa
dc.subject.keywordsProstatectomyspa
dc.subject.keywordsRadiotherapyspa
dc.subject.keywordsNeoplasm metastasisspa
dc.subject.keywordsMetastatic prostate cancerspa
dc.subject.keywordsProstata cancerspa
dc.publisher.programUrología Oncológicaspa
dc.creator.degreenameEspecialista en Urología Oncológicaspa
dc.subject.decsNeoplasias de la Próstataspa
dc.subject.decsRadiocirugiaspa
dc.subject.decsRecurrencia Local de Neoplasiaspa
dc.contributor.corporatenameInstituto Nacional de Cancerologiaspa
dc.contributor.corporatenamePROTOCOLO SWOG S1802spa
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyFacultad de Medicinaspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.creativecommonsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.relation.references1. Sanda MG, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 20;358(12):1250-61, 2008.spa
dc.relation.references2. Gore JL, et al. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 101(12):888-92, 20092. Gore JL, et al. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 101(12):888-92, 2009spa
dc.relation.references4. fSanda MG, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 20;358(12):1250-61, 2008.spa
dc.relation.references7. Gore JL, et al. Correlates of bother following treatment for clinically localized prostate cancer. J Urol 184(4):1309-15, 2010.spa
dc.relation.references8. Wei JT, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 56(6):899-905, 2000.spa
dc.relation.references9. Martin NE, et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 67(3):460-7, 2015.spa
dc.relation.references10. Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:365-76, 1993.spa
dc.relation.references11. Morgans AK, et al. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach. Eur Urol.;68(5):891-8, 2015.spa
dc.relation.references12. Wei JT, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 56(6):899-905, 2000.spa
dc.relation.references13. Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:365-76, 1993.spa
dc.subject.proposalProstatectomiaspa
dc.subject.proposalRadioterapiaspa
dc.subject.proposalNeoplasia metastasicaspa
dc.subject.proposalCancer de prostata metastasicospa
dc.subject.proposalCáncer de prostataspa
dc.publisher.grantorUniversidad Militar Nueva Granadaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1f*
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.instnameinstname:Universidad Militar Nueva Granadaspa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Militar Nueva Granadaspa
dc.identifier.repourlrepourl:https://repository.unimilitar.edu.cospa
dc.rights.localAcceso abiertospa
dc.coverage.sedeMedicinaspa


Files in this item

Thumbnail
Name:
BecerraMendezLuisMiguel2021.pdf
Size:
1.145Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/